Vera Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 10, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 10, 2024
VERA$30.03-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Class A Common Stock · AdditionalPaid-in · Accumulated Other · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Comprehensive Income (Loss) | Deficit | Equity | |
| Balance as of December 31, 2023 | 44,452,161 | $44 | $410,492 | $251 | $(309,102) | $101,685 |
| Issuance of common stock from underwritten follow-on offering, net of offering costs | 9,274,194 | 9 | 269,583 | — | — | 269,592 |
| Issuance of common stock pursuant to exercise of options | 708,897 | 1 | 6,612 | — | — | 6,613 |
| Issuance of common stock upon vesting of restricted stock units | 938 | — | — | — | — | — |
| Issuance of common stock pursuant to employee stock purchase plan | 21,181 | — | 298 | — | — | 298 |
| Proceeds from short swing settlement | — | — | 37 | — | — | 37 |
| Stock-based compensation | — | — | 4,124 | — | — | 4,124 |
| Unrealized loss on marketable securities | — | — | — | (424) | — | (424) |
| Net loss | — | — | — | — | (28,383) | (28,383) |
| Balances as of March 31, 2024 | 54,457,371 | $54 | $691,146 | $(173) | $(337,485) | $353,542 |
| Class A Common Stock · AdditionalPaid-in · Accumulated Other · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Comprehensive Income (Loss) | Deficit | Equity | |
| Balance as of December 31, 2022 | 27,800,861 | $28 | $290,216 | $(224) | $(213,112) | $76,908 |
| Issuance of common stock from underwritten follow-on offering, net of offering costs | 16,428,572 | 16 | 107,727 | — | — | 107,743 |
| Issuance of common stock pursuant to exercise of options | 3,750 | — | 65 | — | — | 65 |
| Issuance of common stock pursuant to employee stock purchase plan | 27,926 | — | 175 | — | — | 175 |
| Stock-based compensation | — | — | 2,667 | — | — | 2,667 |
| Unrealized loss on marketable securities | — | — | — | 220 | — | 220 |
| Net loss | — | — | — | — | (30,069) | (30,069) |
| Balances as of March 31, 2023 | 44,261,109 | $44 | $400,850 | $(4) | $(243,181) | $157,709 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.